Selected research
Industry Research
Oncology Injection Drug Industry Research Report 2026
Market perspective
The global Oncology Injection Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Oncology Injection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Oncology Injection Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Oncology Injection Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Oncology Injection Drug include AdvaCare, Allos Therapeutics, Alza, Celgene, CordenPharma, Debiopharm, Ferring Pharmaceuticals, Genzyme and Merrimack, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Oncology Injection Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oncology Injection Drug Market by Company
AdvaCare
Allos Therapeutics
Alza
Celgene
CordenPharma
Debiopharm
Ferring Pharmaceuticals
Genzyme
Merrimack
Millennium Pharmaceuticals
Pharmascience
Praecis Pharmaceuticals
S.G. Biopharm
Taj Oncology
Eli Lilly
Oncology Injection Drug Segment by Type
Central Nervous System
Circulatory/Musculoskeletal System
Organs
Other
Oncology Injection Drug Segment by Application
Myeloma
Lymphoma
Prostate Cancer
Other
Oncology Injection Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Injection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology Injection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Injection Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Oncology Injection Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Oncology Injection Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Oncology Injection Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Central Nervous System
- Circulatory/Musculoskeletal System
- Organs
- Other
Applications
- Myeloma
- Lymphoma
- Prostate Cancer
- Other
Companies covered
- AdvaCare
- Allos Therapeutics
- Alza
- Celgene
- CordenPharma
- Debiopharm
- Ferring Pharmaceuticals
- Genzyme
- Merrimack
- Millennium Pharmaceuticals
- Pharmascience
- Praecis Pharmaceuticals
- S.G. Biopharm
- Taj Oncology
- Eli Lilly
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Oncology Injection Drug Market Size (2021-2032)
- 2.2.2 Global Oncology Injection Drug Sales (2021-2032)
- 2.2.3 Global Oncology Injection Drug Market Average Price (2021-2032)
- 2.3 Oncology Injection Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Central Nervous System
- 2.3.3 Circulatory/Musculoskeletal System
- 2.3.4 Organs
- 2.3.5 Other
- 2.4 Oncology Injection Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Myeloma
- 2.4.3 Lymphoma
- 2.4.4 Prostate Cancer
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Oncology Injection Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Oncology Injection Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Oncology Injection Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Oncology Injection Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Oncology Injection Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Oncology Injection Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Oncology Injection Drug, Product Type & Application
- 3.8 Global Manufacturers of Oncology Injection Drug, Established Date
- 3.9 Global Oncology Injection Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AdvaCare
- 4.1.1 AdvaCare Company Information
- 4.1.2 AdvaCare Business Overview
- 4.1.3 AdvaCare Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AdvaCare Oncology Injection Drug Product Portfolio
- 4.1.5 AdvaCare Recent Developments
- 4.2 Allos Therapeutics
- 4.2.1 Allos Therapeutics Company Information
- 4.2.2 Allos Therapeutics Business Overview
- 4.2.3 Allos Therapeutics Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Allos Therapeutics Oncology Injection Drug Product Portfolio
- 4.2.5 Allos Therapeutics Recent Developments
- 4.3 Alza
- 4.3.1 Alza Company Information
- 4.3.2 Alza Business Overview
- 4.3.3 Alza Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Alza Oncology Injection Drug Product Portfolio
- 4.3.5 Alza Recent Developments
- 4.4 Celgene
- 4.4.1 Celgene Company Information
- 4.4.2 Celgene Business Overview
- 4.4.3 Celgene Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Celgene Oncology Injection Drug Product Portfolio
- 4.4.5 Celgene Recent Developments
- 4.5 CordenPharma
- 4.5.1 CordenPharma Company Information
- 4.5.2 CordenPharma Business Overview
- 4.5.3 CordenPharma Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 CordenPharma Oncology Injection Drug Product Portfolio
- 4.5.5 CordenPharma Recent Developments
- 4.6 Debiopharm
- 4.6.1 Debiopharm Company Information
- 4.6.2 Debiopharm Business Overview
- 4.6.3 Debiopharm Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Debiopharm Oncology Injection Drug Product Portfolio
- 4.6.5 Debiopharm Recent Developments
- 4.7 Ferring Pharmaceuticals
- 4.7.1 Ferring Pharmaceuticals Company Information
- 4.7.2 Ferring Pharmaceuticals Business Overview
- 4.7.3 Ferring Pharmaceuticals Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Ferring Pharmaceuticals Oncology Injection Drug Product Portfolio
- 4.7.5 Ferring Pharmaceuticals Recent Developments
- 4.8 Genzyme
- 4.8.1 Genzyme Company Information
- 4.8.2 Genzyme Business Overview
- 4.8.3 Genzyme Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Genzyme Oncology Injection Drug Product Portfolio
- 4.8.5 Genzyme Recent Developments
- 4.9 Merrimack
- 4.9.1 Merrimack Company Information
- 4.9.2 Merrimack Business Overview
- 4.9.3 Merrimack Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Merrimack Oncology Injection Drug Product Portfolio
- 4.9.5 Merrimack Recent Developments
- 4.10 Millennium Pharmaceuticals
- 4.10.1 Millennium Pharmaceuticals Company Information
- 4.10.2 Millennium Pharmaceuticals Business Overview
- 4.10.3 Millennium Pharmaceuticals Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Millennium Pharmaceuticals Oncology Injection Drug Product Portfolio
- 4.10.5 Millennium Pharmaceuticals Recent Developments
- 4.11 Pharmascience
- 4.11.1 Pharmascience Company Information
- 4.11.2 Pharmascience Business Overview
- 4.11.3 Pharmascience Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pharmascience Oncology Injection Drug Product Portfolio
- 4.11.5 Pharmascience Recent Developments
- 4.12 Praecis Pharmaceuticals
- 4.12.1 Praecis Pharmaceuticals Company Information
- 4.12.2 Praecis Pharmaceuticals Business Overview
- 4.12.3 Praecis Pharmaceuticals Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Praecis Pharmaceuticals Oncology Injection Drug Product Portfolio
- 4.12.5 Praecis Pharmaceuticals Recent Developments
- 4.13 S.G. Biopharm
- 4.13.1 S.G. Biopharm Company Information
- 4.13.2 S.G. Biopharm Business Overview
- 4.13.3 S.G. Biopharm Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 S.G. Biopharm Oncology Injection Drug Product Portfolio
- 4.13.5 S.G. Biopharm Recent Developments
- 4.14 Taj Oncology
- 4.14.1 Taj Oncology Company Information
- 4.14.2 Taj Oncology Business Overview
- 4.14.3 Taj Oncology Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Taj Oncology Oncology Injection Drug Product Portfolio
- 4.14.5 Taj Oncology Recent Developments
- 4.15 Eli Lilly
- 4.15.1 Eli Lilly Company Information
- 4.15.2 Eli Lilly Business Overview
- 4.15.3 Eli Lilly Oncology Injection Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Eli Lilly Oncology Injection Drug Product Portfolio
- 4.15.5 Eli Lilly Recent Developments
5 Global Oncology Injection Drug Market Scenario by Region
- 5.1 Global Oncology Injection Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Oncology Injection Drug Sales by Region: 2021-2032
- 5.2.1 Global Oncology Injection Drug Sales by Region: 2021-2026
- 5.2.2 Global Oncology Injection Drug Sales by Region: 2027-2032
- 5.3 Global Oncology Injection Drug Revenue by Region: 2021-2032
- 5.3.1 Global Oncology Injection Drug Revenue by Region: 2021-2026
- 5.3.2 Global Oncology Injection Drug Revenue by Region: 2027-2032
- 5.4 North America Oncology Injection Drug Market Facts & Figures by Country
- 5.4.1 North America Oncology Injection Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Oncology Injection Drug Sales by Country (2021-2032)
- 5.4.3 North America Oncology Injection Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Oncology Injection Drug Market Facts & Figures by Country
- 5.5.1 Europe Oncology Injection Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Oncology Injection Drug Sales by Country (2021-2032)
- 5.5.3 Europe Oncology Injection Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Oncology Injection Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Oncology Injection Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Oncology Injection Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Oncology Injection Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Oncology Injection Drug Market Facts & Figures by Country
- 5.7.1 South America Oncology Injection Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Oncology Injection Drug Sales by Country (2021-2032)
- 5.7.3 South America Oncology Injection Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Oncology Injection Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Oncology Injection Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Oncology Injection Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Oncology Injection Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Oncology Injection Drug Sales by Type (2021-2032)
- 6.1.1 Global Oncology Injection Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Oncology Injection Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Oncology Injection Drug Revenue by Type (2021-2032)
- 6.2.1 Global Oncology Injection Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Oncology Injection Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Oncology Injection Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Oncology Injection Drug Sales by Application (2021-2032)
- 7.1.1 Global Oncology Injection Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Oncology Injection Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Oncology Injection Drug Revenue by Application (2021-2032)
- 7.2.1 Global Oncology Injection Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Oncology Injection Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Oncology Injection Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Oncology Injection Drug Value Chain Analysis
- 8.1.1 Oncology Injection Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Oncology Injection Drug Production Mode & Process
- 8.2 Oncology Injection Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Oncology Injection Drug Distributors
- 8.2.3 Oncology Injection Drug Customers
9 Global Oncology Injection Drug Analyzing Market Dynamics
- 9.1 Oncology Injection Drug Industry Trends
- 9.2 Oncology Injection Drug Industry Drivers
- 9.3 Oncology Injection Drug Industry Opportunities and Challenges
- 9.4 Oncology Injection Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst